Research Support Centre
Technology Platforms


Computational Phenomics Platform (CPP) by Experimental Drug Development Centre (EDDC)

High Content Analysis (HCA) involves the extraction of multi-parametric data from cellular/sub-cellular images to quantify phenotypic alterations in cells. A High Content Screening (HCS) approach entails screening of thousands of compounds in high throughput fashion, generating millions/billions of image-based data. Deriving meaningful biological insights from HCA and HCS requires expertise in large-scale image analysis and cellular imaging. For more complex problems, techniques in Artificial Intelligence/Machine Learning (AI/ML) and multi-dimensional -omics data analytics are used to model and predict phenotypic behaviors associated with drug response.

Through years of involvement in research programs with the industry, other institutions and clinical advocates in Singapore and abroad, the Computational Phenomics Platform has acquired extensive experience in cellular image analysis for different models (cell-line, spheroids, organoids), AI/ML from large-scale image-based data, -omics data analytics (phenomics, transcriptomics, proteomics, genomics) and HTP screening data analytics.

CPP provides customized algorithms to convert high quality images to quantitative data for target validation, hit identification and confirmation.


Key Capabilities

  • Innovative analytics and visualization for High Throughput Screening (HTS) and High Content Screening (HCS) assays
  • Image/Video Analytics of cellular assays, spheroids and organoids at single-cell resolution
  • Utilize Machine/Deep learning to predict complex biological outcomes from HTS and HCS data
  • Inter-omics data analytics (Transcriptomics, Proteomics, Genomics, Phenomics)
  • Structure-based modelling and screening


Key Expertise

  • Deep content screening (DCS): AI-driven image-based phenotypic screening
  • 4D high content screening of 3D tumor spheroids (Patent WO/2019/035766)
  • Customization and automation of non image-based HTS/image-based HCS analysis and visualization pipelines
  • Integration of other -omics data with drug response phenotypic profiles; Multiplexed HTS/HCS
  • Combinatorial in-silico and in-vitro screening



4D High Content Screening




Computational Phenomics Platform (CPP) is part of the EDDC Academic Research Organisation or EARO, a Fee-for-Service initiative by the Experimental Drug Development Centre (EDDC). Founded in 2020, EARO was conceived to provide greater access to EDDC’s rich scientific expertise and state of the art technology platforms to the academic and industry researchers in the biomedical ecosystem who aspire to embark on a journey of translating their research into drug candidates. EARO comprises primarily of 5 core drug discovery platforms headed by scientists with decades of experience.  The EARO Platforms include High Throughput Screening (HTS), Fragment Based Screening (FBS), Protein Crystallography (XRAY), High Throughput Phenomics (HTP) and Computational Phenomics Platforms (CPP). Together, EARO groups have engaged with more than 70 academic and industry partners.

Visit for more information  or email